MEDP Key Statistics, Chart & Performance
The current stock price of MEDP is 557.9 USD. In the past month the price decreased by -5.65%. In the past year, price increased by 61.28%.
MEDP Latest News, Press Relases and Analysis
MEDP Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 25.55 | 215.01B | ||
| DHR | DANAHER CORP | 29.36 | 159.87B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 174.99 | 53.17B | ||
| A | AGILENT TECHNOLOGIES INC | 25.03 | 39.60B | ||
| IQV | IQVIA HOLDINGS INC | 19.11 | 37.85B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 33.31 | 28.47B | ||
| WAT | WATERS CORP | 30.34 | 22.94B | ||
| ILMN | ILLUMINA INC | 30.93 | 20.61B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 37.84 | 19.25B | ||
| TEM | TEMPUS AI INC | N/A | 12.56B | ||
| RVTY | REVVITY INC | 20.98 | 11.39B | ||
| CRL | CHARLES RIVER LABORATORIES | 18.3 | 9.50B |
Related stock screener links
About MEDP
Company Profile
Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company is headquartered in Cincinnati, Ohio and currently employs 6,000 full-time employees. The company went IPO on 2016-08-11. The firm partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The firm also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.
Company Info
MEDPACE HOLDINGS INC
5375 Medpace Way
Cincinnati OHIO 45227 US
CEO: August J. Troendle
Employees: 6000
Phone: 15135799911
MEDPACE HOLDINGS INC / MEDP FAQ
What does MEDP do?
Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company is headquartered in Cincinnati, Ohio and currently employs 6,000 full-time employees. The company went IPO on 2016-08-11. The firm partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The firm also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.
What is the stock price of MEDPACE HOLDINGS INC today?
The current stock price of MEDP is 557.9 USD. The price decreased by -1.46% in the last trading session.
Does MEDPACE HOLDINGS INC pay dividends?
MEDP does not pay a dividend.
How is the ChartMill rating for MEDPACE HOLDINGS INC?
MEDP has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
Which stock exchange lists MEDP stock?
MEDP stock is listed on the Nasdaq exchange.
Can you provide the PE ratio for MEDP stock?
The PE ratio for MEDPACE HOLDINGS INC (MEDP) is 39.01. This is based on the reported non-GAAP earnings per share of 14.3 and the current share price of 557.9 USD.
Can you provide the upcoming earnings date for MEDPACE HOLDINGS INC?
MEDPACE HOLDINGS INC (MEDP) will report earnings on 2026-02-09, after the market close.
MEDP Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to MEDP. When comparing the yearly performance of all stocks, MEDP is one of the better performing stocks in the market, outperforming 90.68% of all stocks.
MEDP Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to MEDP. Both the health and profitability get an excellent rating, making MEDP a very profitable company, without any liquidiy or solvency issues.
MEDP Financial Highlights
Over the last trailing twelve months MEDP reported a non-GAAP Earnings per Share(EPS) of 14.3. The EPS increased by 25.22% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 18.36% | ||
| ROA | 24.7% | ||
| ROE | 147.46% | ||
| Debt/Equity | 0 |
MEDP Forecast & Estimates
18 analysts have analysed MEDP and the average price target is 547.08 USD. This implies a price decrease of -1.94% is expected in the next year compared to the current price of 557.9.
For the next year, analysts expect an EPS growth of 19.53% and a revenue growth 19.22% for MEDP